

ABSTRACT

This invention attempts to provide a composition for intranasal administration which has markedly lower risk of developing side effects compared to oral formulation, which promptly exhibits analgesic effects, and which has excellent bioavailability.

The composition for nasal absorption comprises a carrier of calcium carbonate and/or calcium phosphate having an average particle size of 500 μm or less and an effective dose of an opioid analgesic uniformly distributed and attached to the carrier.